Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Z-FEAM radioimmunotherapy conditioning before autologous transplant in CD20+ relapsed/refractory lymphoma
2008-006899-30Phase 2Terminated
- Sponsor
- Istituti Fisioterapici Ospitalieri
- Start
- Dec 2008
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ibritumomab tiuxetan, fotemustine, cytarabine, etoposide and melphalan in Hodgkin lymphoma (HL) and mature B-cell lymphoma, sponsored by Istituti Fisioterapici Ospitalieri. Primary endpoint: Hematological and extrahematological toxicity rate. Started Dec 2008; status: terminated.
02
Drugs
ibritumomab tiuxetanfotemustinecytarabineetoposidemelphalan
03
Conditions
Hodgkin lymphoma (HL)mature B-cell lymphoma
Beyond the preview
Go deeper on 2008-006899-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006899-30.